OpenLB
Open Library of Bioscience
Advanced Search
Molecular therapy. Methods & clinical development
Jun 16, 2017;5 66-75.

Dendritic Cell Therapies for Hematologic Malignancies.

Matthew Weinstock, Jacalyn Rosenblatt, David Avigan
Author Information
  1. Matthew Weinstock: Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  2. Jacalyn Rosenblatt: Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  3. David Avigan: Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
PMID: 28480306 DOI: 10.1016/j.omtm.2017.03.004

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component of the immune system's role in the recognition, elimination, and tolerance of cancer. The unique immunologic capabilities of DCs have recently been harnessed for therapeutic use with the creation of DC-based anti-tumor vaccines, several of which have moved into testing in clinical trials for hematologic malignancies. This review summarizes how treatment strategies using DC-based anti-tumor vaccines are advancing immunotherapeutic options for these diseases.

Keywords

AML cancer immunotherapy dendritic cell multiple myeloma tumor immunology vaccine

References

  1. J Clin Oncol. 2008 Sep 20;26(27):4410-7 [PMID: 18802153]
  2. J Immunol. 2016 Sep 1;197(5):1864-76 [PMID: 27465530]
  3. J Immunother. 2005 Nov-Dec;28(6):564-75 [PMID: 16224274]
  4. J Immunother. 2003 Sep-Oct;26(5):432-9 [PMID: 12973032]
  5. Biol Blood Marrow Transplant. 2000;6(6):621-7 [PMID: 11128812]
  6. Cell. 2001 Aug 10;106(3):255-8 [PMID: 11509172]
  7. BMC Cancer. 2014 May 15;14:335 [PMID: 24886161]
  8. Oncoimmunology. 2013 Mar 1;2(3):e23431 [PMID: 23802086]
  9. Cancer Immunol Immunother. 2012 Jun;61(6):865-79 [PMID: 22086161]
  10. Cancer Res. 2001 Sep 1;61(17):6451-8 [PMID: 11522640]
  11. Clin Cancer Res. 2013 Apr 15;19(8):2048-60 [PMID: 23344265]
  12. Cancer J. 2016 Jan-Feb;22(1):27-33 [PMID: 26841014]
  13. Oncoimmunology. 2015 Aug 31;5(3):e1085146 [PMID: 27141339]
  14. J Clin Oncol. 2009 Jun 20;27(18):3036-43 [PMID: 19414675]
  15. Am J Hematol. 2005 Sep;80(1):6-11 [PMID: 16138340]
  16. J Exp Med. 2001 Dec 17;194(12):1823-34 [PMID: 11748283]
  17. Blood. 2011 Jan 13;117(2):393-402 [PMID: 21030562]
  18. Science. 2007 Jan 5;315 (5808):107-11 [PMID: 17204652]
  19. Exp Hematol. 2011 Apr;39(4):424-433.e2 [PMID: 21216276]
  20. Blood. 1999 Apr 1;93(7):2411-9 [PMID: 10090953]
  21. Oncotarget. 2016 Mar 15;7(11):12840-56 [PMID: 26883197]
  22. Clin Cancer Res. 2009 May 15;15(10):3406-15 [PMID: 19401350]
  23. Target Oncol. 2014 Sep;9(3):225-37 [PMID: 23852664]
  24. Nat Med. 1996 Jan;2(1):52-8 [PMID: 8564842]
  25. Science. 2015 May 15;348(6236):803-8 [PMID: 25837513]
  26. Clin Exp Immunol. 2012 Nov;170(2):167-77 [PMID: 23039887]
  27. Clin Cancer Res. 2013 Jul 1;19(13):3640-8 [PMID: 23685836]
  28. Sci Transl Med. 2016 Dec 7;8(368):368ra171 [PMID: 27928025]
  29. Cancer Immun. 2003 Jul 23;3:9 [PMID: 12875607]
  30. Anticancer Res. 2014 Aug;34(8):3917-24 [PMID: 25075013]
  31. Clin Cancer Res. 2004 Dec 15;10(24):8309-17 [PMID: 15623607]
  32. Cancer Res. 2002 May 15;62(10):2861-8 [PMID: 12019165]
  33. Blood. 2008 Apr 15;111(8):4245-53 [PMID: 18258799]
  34. J Immunother. 2005 Mar-Apr;28(2):158-68 [PMID: 15725960]
  35. Haematologica. 2002 Apr;87(4):400-7 [PMID: 11940484]
  36. J Exp Med. 1994 Nov 1;180(5):1841-7 [PMID: 7525840]
  37. Eur J Immunol. 2001 Oct;31(10):3026-37 [PMID: 11592079]
  38. Blood. 2012 May 31;119(22):5182-90 [PMID: 22510877]
  39. J Clin Oncol. 2011 Jul 10;29(20):2787-94 [PMID: 21632504]
  40. J Immunol. 2004 Aug 15;173(4):2780-91 [PMID: 15294997]
  41. Blood. 2009 Jan 1;113(1):18-27 [PMID: 18809757]
  42. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2880-5 [PMID: 15710900]
  43. Br J Haematol. 2002 May;117(2):297-305 [PMID: 11972511]
  44. J Immunother. 2011 Jun;34(5):409-18 [PMID: 21577144]
  45. Hum Gene Ther. 2013 Feb;24(2):220-37 [PMID: 23311414]
  46. Allergy. 2017 Feb;72 (2):221-231 [PMID: 27138374]
  47. J Immunol Methods. 2004 Feb 15;285(2):171-80 [PMID: 14980432]
  48. Leukemia. 2004 Nov;18(11):1810-5 [PMID: 15385926]
  49. Cancer Immunol Immunother. 2002 Aug;51(6):299-310 [PMID: 12111118]
  50. J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301 [PMID: 16985248]
  51. Cancer Immunol Immunother. 2013 Jan;62(1):39-49 [PMID: 22733396]
  52. Science. 2006 Sep 29;313(5795):1960-4 [PMID: 17008531]
  53. Blood. 2003 Feb 1;101(3):977-82 [PMID: 12393470]
  54. Immunology. 2013 Sep;140(1):22-30 [PMID: 23621371]
  55. Oncoimmunology. 2016 Jun 27;5(7):e1196312 [PMID: 27622051]
  56. Cancer Res. 2006 Apr 15;66(8):4496-502 [PMID: 16618777]
  57. Leukemia. 2003 Jul;17(7):1424-6 [PMID: 12835739]
  58. Cancer Immunol Immunother. 2013 Aug;62(8):1381-92 [PMID: 23728352]
  59. Eur J Immunol. 2010 Oct;40(10):2667-76 [PMID: 20821731]
  60. Am J Hematol. 2009 Dec;84(12):799-802 [PMID: 19899131]
  61. Immunology. 2007 Jan;120(1):90-102 [PMID: 17073943]
  62. Cancer Res. 2005 Nov 1;65(21):10041-9 [PMID: 16267030]
  63. Leukemia. 2008 May;22(5):1007-17 [PMID: 18323802]
  64. Br J Haematol. 2015 May;169(3):356-67 [PMID: 25612920]
  65. Hum Vaccin Immunother. 2014;10(11):3261-9 [PMID: 25625929]
  66. Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12782-7 [PMID: 26417101]
  67. J Immunother. 2011 Jan;34(1):100-6 [PMID: 21150718]
  68. Br J Haematol. 1999 Dec;107(3):648-55 [PMID: 10583271]
  69. Blood. 2005 Jul 1;106(1):167-74 [PMID: 15761016]
  70. Cytotherapy. 2006;8(3):290-8 [PMID: 16793737]
  71. Leukemia. 2005 Sep;19(9):1621-7 [PMID: 15990861]
  72. Blood. 2000 Aug 15;96(4):1317-26 [PMID: 10942373]
  73. Immunity. 2002 Aug;17(2):211-20 [PMID: 12196292]
  74. Blood. 2002 Mar 1;99(5):1517-26 [PMID: 11861263]
  75. Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9 [PMID: 20631300]
  76. J Immunol. 2013 Mar 15;190(6):2712-9 [PMID: 23418627]
  77. Int J Cancer. 1999 Oct 8;83(2):215-22 [PMID: 10471530]
  78. Cancer Immun. 2010 Aug 23;10:8 [PMID: 20726502]
  79. J Clin Oncol. 2014 Jun 10;32(17):1797-803 [PMID: 24799467]
  80. Blood. 1999 Jul 15;94(2):673-83 [PMID: 10397734]
  81. Leuk Lymphoma. 2004 Jul;45(7):1419-28 [PMID: 15359643]
  82. Nat Med. 1999 Oct;5(10):1171-7 [PMID: 10502821]
  83. Br J Haematol. 2007 May;137(4):297-306 [PMID: 17408402]
  84. Br J Haematol. 2010 Sep;150(5):554-64 [PMID: 20618329]
  85. J Immunol. 2003 May 15;170(10):5317-25 [PMID: 12734382]
  86. J Transl Med. 2013 Jul 09;11:166 [PMID: 23837662]
  87. Br J Haematol. 2000 Mar;108(4):805-16 [PMID: 10792287]
  88. Expert Opin Biol Ther. 2016 Sep;16(9):1113-23 [PMID: 27238400]
  89. Cancer Res. 2004 Jun 15;64(12):4357-65 [PMID: 15205352]
  90. Oncogene. 2014 Sep 18;33(38):4623-31 [PMID: 24141774]
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0DendriticcellsDCscancerDC-basedanti-tumorvaccinespotentantigen-presentingthat constitutemajorcomponentimmunesystem'srolerecognitioneliminationtoleranceuniqueimmunologiccapabilitiesrecentlyharnessedtherapeuticusecreationseveralmovedtestingclinicaltrialshematologicmalignanciesreviewsummarizestreatmentstrategiesusingadvancingimmunotherapeuticoptionsdiseasesCellTherapiesHematologicMalignanciesAMLimmunotherapydendriticcellmultiplemyelomatumorimmunologyvaccine

Similar Articles

Cited By